Catheter Precision financials
$0.1467−4.55%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $819.0K | $420.0K | $442.0K |
| Gross profit | $756.0K | $378.0K | $412.0K |
| Gross margin | 92.3% | 90.0% | 93.2% |
| Operating income | -$14.1M | -$11.2M | -$78.1M |
| Net income | -$17.2M | -$21.8M | -$71.4M |
| Net margin | −2098.0% | −5190.7% | −16147.5% |
| Diluted EPS | $-15.90 | $-126.91 | $-2467.72 |
| EBITDA | -$12.0M | -$9.1M | -$15.1M |
| Operating cash flow | -$8.3M | -$9.3M | -$20.6M |
| Free cash flow | -$8.3M | -$9.3M | -$20.7M |
| Diluted shares | 1.1M | 0.2M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $88.0K | $2.9M | $3.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $3.4M | $177.0K | $184.0K |
| Total assets | $15.9M | $27.8M | $30.7M |
| Total liabilities | $9.2M | $16.0M | $9.5M |
| Shareholders' equity | $6.7M | $11.8M | $21.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology